Tg Therapeutics (TGTX) Return on Sales (2017 - 2026)

Tg Therapeutics' Return on Sales history runs 10 years deep, the most recent figure standing at 0.0% for Q1 2026.

• On a quarterly basis, Return on Sales changed 0.0% year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.01%, a 1.0% increase from a year earlier, with the FY2025 full-year figure at 0.01%, up 1.0% from the prior year.
• Return on Sales retreated to 0.0% in Q1 2026 per TGTX's latest filing, from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.02% in Q3 2025 and bottomed at 10.48% in Q4 2022.
• The 5-year median for Return on Sales is 0.0% (2025), against an average of 0.95%.
• Across the five-year window, Return on Sales plunged 1006 bps in 2022 and jumped 1047 bps in 2023, its largest moves.
• Year by year, Return on Sales stood at 10.48% in 2022, then surged by 100 bps to 0.0% in 2023, then soared by 196 bps to 0.0% in 2024, then slumped by 58 bps to 0.0% in 2025, then dropped by 21 bps to 0.0% in 2026.
• Per Business Quant, the three latest TGTX Return on Sales figures stand at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.02% (Q3 2025).